A novel standardized deep sequencing-based assay for hepatitis C virus genotype determination

Area of Science:

• Virology
• Molecular Biology
• Infectious Diseases

Background:

• Accurate Hepatitis C virus (HCV) genotype and subtype identification is essential for effective anti-HCV therapy selection.
• Current methods may not identify all HCV subtypes or mixed infections, highlighting the need for advanced genotyping systems.
• Deep sequencing combined with phylogenetic analysis offers a high-resolution approach for comprehensive HCV profiling.

Purpose of the Study:

• To evaluate the performance of the Sentosa SQ HCV Genotyping Assay, a novel deep sequencing assay.
• To assess its accuracy in identifying HCV genotypes and subtypes in clinical samples.
• To determine its suitability for guiding anti-HCV treatment decisions.

Main Methods:

• Utilized deep sequencing of the Hepatitis C virus nonstructural 5B (NS5B) gene region.
• Employed phylogenetic analysis for genotype and subtype determination.
• Compared results with Sanger sequencing, the established reference method.

Main Results:

• High concordance was observed between the deep sequencing assay and Sanger sequencing for genotypes 1-6 and 1a/1b subtypes.
• Accurate subtyping was achieved for genotypes 4, 5, and 6.
• Some discrepancies were noted specifically for Hepatitis C virus genotype 2 subtyping.

Conclusions:

• The Sentosa SQ HCV Genotyping Assay demonstrates adequate performance for clinical use in tailoring anti-HCV therapy.
• Further enhancements, including analyzing longer NS5B fragments and expanding reference databases, could optimize its utility.
• This deep sequencing approach holds potential as a preferred method for future HCV genotyping and subtyping in clinical practice and research.